Siemens Healthineers Courts Lab Diagnostics and Radiotherapy Growth While Analysts Split Ahead of Q4
Published on 10/08/2026 at 18:31 | Editorial boerse-global.de
Siemens Healthineers is stacking up fresh product initiatives on two fronts — laboratory diagnostics and radiation oncology — as the German medtech group counts down to its fourth-quarter earnings release. The company said on October 1 that it had struck a strategic alliance with Truvian Health to help advance that partner's TruVerus blood-testing platform toward market readiness. Under the arrangement, Siemens Healthineers will contribute development support, technical resources, manufacturing know-how and commercial advice, leaning on its industrial scale to push the platform through the lengthy validation work that typically separates a promising assay system from a revenue-generating product.
The Truvian tie-up slots into a broader effort by management to broaden the pipeline with novel systems. Among the most closely watched is Accela, a radiotherapy platform built on the NeoArc system and unveiled on September 27. According to the company, the technology can deliver stereotactic treatments within a single breath-hold cycle and multi-target irradiation in as little as 60 seconds. At the time of the presentation, FDA clearance was still pending, leaving the system unavailable in any market for now. Such launches underscore the group's ambition to shorten oncology treatment times and speed up clinical workflows — though in medtech, new hardware usually takes considerable time to show up in revenue because of elaborate review processes.
Two Houses, Two Very Different Targets
Analysts are not reading the story the same way. Deutsche Bank Research on Monday reiterated a "Hold" rating with a price target of EUR 39, implying only limited upside from current levels. JPMorgan takes a far rosier view: analyst David Adlington kept an "Overweight" rating as of September 29, according to dpa-AFX, with a target of EUR 57.40. His confidence rests chiefly on the market opportunity opened up by the newly introduced product lines. Adlington singled out Accela's speed as a potential source of meaningful efficiency gains for clinics.
Clinical imaging is adding its own momentum. On September 24, Siemens Healthineers and the Bad Neustadt campus of RHÖN-KLINIKUM reported the use of the NAEOTOM Alpha.Peak photon-counting CT scanner. In neuroradiology, the system is being deployed to visualize narrowing of cerebral arteries and aneurysms in fine detail.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
A Patent Complaint, a Leadership Switch and a Buyback
Not everything in the news flow has been product-driven. Roughly a week ago, US firm MR Access accused Siemens Healthineers of patent infringement relating to magnetic resonance imaging equipment. The allegations have not been established in court. Since the claim surfaced, the stock has added 0.6%.
On the personnel side, the company named Guilherme Marques on Tuesday as managing director for the UK and Ireland. He succeeds Ghada Trotabas, who takes over global leadership of Enterprise Services. Marques is tasked with strengthening the group's market position in both countries, while Trotabas will coordinate the worldwide service business.
Meanwhile, the company continues to support its share price through an ongoing buyback. Since June, more than three million shares have been repurchased, with several million already acquired by early October.
Where the Stock Stands
The equity has been trading in a demanding environment. Most recently it changed hands at EUR 38.51, up 0.7% on the day, though it remains down 14% since the start of the year. In a separate reading, the shares were quoted at EUR 38.16, a decline of 0.2%.
What happens next will likely hinge on the November 5 report, when Siemens Healthineers publishes results for the fourth quarter of fiscal 2026 and discusses them with analysts on a conference call. Market watchers will be looking for signs of how far the recent innovations have begun to feed through into order intake and margins.
Ad
Siemens Healthineers Stock: New Analysis - 8 October
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
